Most cancer treatments don’t actually kill cancer — they just manage it.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, reveals the critical difference between cytostatic and cytotoxic therapies — and why precision oncology focuses on the latter. Cytostatic drugs slow tumor growth, but cytotoxic strategies destroy cancer cells while protecting healthy tissue and strengthening the immune system.
Dr. Prato explains how precision oncology combines deep DNA/RNA sequencing, immune profiling, and spatial biology to customize treatment plans that move beyond managing cancer to truly eliminating it. By designing cytotoxic, immune-driven regimens, Envita’s approach has produced dramatically improved response rates and quality of life for patients.
🎯 What You’ll Learn in This Episode:

• The real difference between cytostatic and cytotoxic cancer drugs

• Why most pharmaceutical therapies are designed to manage, not eliminate cancer

• How precision oncology personalizes cytotoxic targeting to kill tumor cells

• The role of immune activation in achieving lasting remissions

• How microdosing and pathway mapping improve quality of life and reduce side effects

• Why combining precision targeting with immune support leads to better outcomes
📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com
📞 Speak to a care coordinator: 866-830-4576
“Managing cancer isn’t enough — it’s time to design care that actually kills it.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493